1. Medtech Insight
  2. >>Business
  3. >>Strategy

Eight Things That Will Fix Medtech Investing

The last five years have been brutal ones for medical device VCs and entrepreneurs, yet there’s still cause for hope. In a series of interviews, we asked venture capitalists, entrepreneurs, and executives: what gives you hope and what makes you optimistic about the future of medtech?

The timing of the news could not have been worse. In January, just a few days before the health care industry was set to meet at the JP Morgan Healthcare Conference in San Francisco, renal denervation – one of the highest profile sectors in medtech – imploded on news that Medtronic PLC’s Symplicity hypertension device didn’t perform well in clinical studies. The news was a kick in the face to an investment sector already on its hands and knees. (See Also see "SYMPLICITY Results Make Life Difficult For Renal Denervation Programs" - In Vivo, 24 January, 2014..) Dissemination of the disappointing trial results happened to coincide with the meteoric post-IPO performance of Intercept Pharmaceuticals Inc., yet another success story that just highlighted the differences between the medtech and biopharmaceutical sectors.

Where did things go so wrong? Clearly, the Symplicity trial results are something future device VCs and executives will see as an unfortunate mile marker in the device sector’s long...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

SAGA Diagnostics Launches Early Breast Cancer MRD Detection Test In US

 
• By Natasha Barrow

SAGA Diagnostics has launched its breast cancer residual and recurrence detection test – Pathlight – in the US. The test’s ultrahigh sensitivity and specificity is rare to see in oncology, the company claimed.

Siemens Healthineers Widens FY25 EPS Range By €0.15 To Absorb Up To €300M In Tariff Costs

 
• By Shubham Singh

The imaging, Varian, and advanced therapies segments – which are more reliant on equipment sales – are more heavily affected, with tariffs applying to roughly 55% of their revenue base. In diagnostics, the company expects minimal exposure due to sufficient US value-added manufacturing.

ConcertAI Launches Generative AI-Powered Precision Suite

 
• By Natasha Barrow

Valued at over $1.9bn, ConcertAI is building on its pre-existing multi-agentic AI SaaS solution CARAai to bring life science customers the new Precision suite of applications: Precision Explorer, Precision Trials, Precision GTM and Precision360.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

More from Business